Constipation is a common condition, especially among older adults and the cause is often multifactorial. Treatment of older adults is often complicated by comorbidities including polypharmacy and ...

Magnesium is one of the most important minerals that our bodies need, catalyzing over 600 biochemical reactions. Yet, loads ...

Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of ...

Xanomeline and trospium chloride is a first-in-class medication that selectively targets the M1 and M4 receptors without blocking D2 receptors.

With Thursday approval from the U.S. Food and Drug Administration for Cobenfy, adults living with schizophrenia will have ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

These included nausea, vomiting, abdominal pain, diarrhea, constipation ... Rybelsus can be an effective treatment for improving blood sugar management in adults with type 2 diabetes.

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name ...

Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults ...